Publication date: Dec 09, 2024
Despite the declining public health emergency status, COVID-19 still poses significant risks, especially for immunocompromised individuals. We aimed to evaluate the effectiveness of tixagevimab-cilgavimab (T-C) prophylaxis in preventing severe COVID-19 in patients with hematologic malignancies (HM) treated with anti-CD20 therapy during the early Omicron variant phase of the pandemic. The European Society of Clinical Microbiology and Infectious Diseases Study Group for Respiratory Viruses (ESGREV) conducted a multicenter retrospective cohort study involving 15 centers from 5 countries. The study included 749 patients with HM treated with anti-CD20 between February 15 and June 30, 2022, comparing 215 who received T-C prophylaxis to 534 who did not. The study revealed a significant reduction in the risk of COVID-19 among patients who received T-C prophylaxis compared to those who did not (11. 2% vs 23. 4%, p
| Concepts | Keywords |
|---|---|
| Cd20 | Anti-CD20 |
| February | COVID-19 |
| Immunocompromised | Hematologic malignancies |
| June | Monoclonal antibodies |
| Severe | Tixagevimab-cilgavimab |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | emergency |
| disease | MESH | hematologic malignancies |
| disease | MESH | Infectious Diseases |
| disease | MESH | Long Covid |